Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Implementação na vida real de um diagnóstico óptico baseado em IA (AI-OD)

17 de setembro de 2026 atualizado por: Centre hospitalier de l'Université de Montréal (CHUM)

Implementação na vida real de uma estratégia de diagnóstico óptico baseada em inteligência artificial para pólipos colorretais diminutos

This is a prospective study that is the first to implement resect and discard and diagnose and leave strategies in real-time practice using stringent documentation and adjudication by 2 expert endoscopists as the gold standard.

The primary aim of this study is to show the accuracy of intracolonoscopy AI-assisted optical diagnosis (CADx; autonomous or with human input) when the AI-assisted optical diagnosis made by the expert endoscopists is used as the reference standard. The specific aims are:

  1. To evaluate the accuracy of intracolonoscopy AI-assisted optical polyp diagnosis (autonomous or with human input) by comparing it to the obtained optical histology diagnoses provided by two independent expert endoscopists as the reference standard.
  2. To evaluate the agreement between the intracolonoscopy AI-assisted optical polyp diagnosis (autonomous or with human input) and the AI-assisted optical diagnosis performed by two independent expert endoscopists.
  3. To determine whether AI-assisted optical polyp diagnosis for diminutive (1-5 mm) polyps can be implemented in routine clinical practice by demonstrating that at least 70% of the approached patients are interested in undergoing AI-assisted optical diagnosis (autonomous or with human input).
  4. To evaluate the cost savings resulting from replacing pathology with AI-assisted optical diagnosis.

Visão geral do estudo

Status

Ativo, não recrutando

Descrição detalhada

All patients who meet the inclusion criteria can be enrolled. Eligible patients will be informed about the study through a consent form that includes information on optical diagnosis (resect and discard, diagnose and leave) and AI/CADx systems. We will ask the patients' willingness to undergo AI-assisted optical diagnosis with endoscopists' input (the first 102 patients) and automomous AI-assisted optical diagnosis (from patient 103 to 204). Subsequently, patients will be asked if they are willing to participate in the study, using AI-assisted optical diagnosis and the "resect and discard" and "diagnose and leave" strategy. If a patient declines to undergo optical diagnosis, they will be asked about the reason for their refusal to participate in the study. The options for their response include:

  1. Concerns regarding undergoing an optical diagnosis.
  2. Reluctance to participate in research projects in general.
  3. Other reasons.
  4. Preference not to answer the question.

Patients who agree to participate in the study will undergo standard colonoscopy procedures with AI-assisted optical diagnosis for all diminutive colorectal polyps identified. High-definition colonoscopes with a joint computer-assisted classification (CADx) support (CAD-EYE software EW10-EC02) will be used.

For the first 102 patients (i.e., the CAD-assisted optical diagnosis with endoscopist's input), the endoscopists will use the CAD-EYE blue light imaging (BLI) mode to enhance the visualization of polyp features. During the optical diagnosis using CADx, the most probable diagnosis (neoplastic or hyperplastic) will be displayed on the endoscopy screen. If the serrated pathology subtype is determined as the most probable histology, the endoscopists will make the final decision. They will also indicate whether their optical diagnosis was made with low or high confidence.

For the second group of 102 patients (i.e., autonomous CADx-assisted optical diagnosis), endoscopists will use CADx and BLI mode to perform optical diagnosis. Based on the CADx diagnosis, all 1-5 mm polyps diagnosed as hyperplastic or neoplastic will be resected and discarded, while those located in the rectosigmoid and diagnosed as hyperplastic will be left in the colon. When high-risk histology features are observed using BLI, in any patient, the endoscopists will inform the research assistant to document them, and the polyp will be sent for pathology examination in accordance with the ASGE PIVI guidelines recommendations. All polyps >5mm will be send for pathology evaluation. Polyp size will be measured using virtual scale technology integrated in the computer-assisted system (CAD) to ensure an accurate polyp sizing.18 A research assistant will document the characteristics of the detected polyps (i.e., location, size, morphology, AI-assisted intracolonoscopy and endoscopists optical diagnoses). All identified colorectal polyps will be removed following standard polypectomy practices. The entire colonoscopy procedures will be video recorded for quality assurance purposes. All diminutive polyps will be resected and discarded as part of the resect and discard strategy. Additionally, diminutive polyps located in the rectosigmoid colon will be detected and left in situ (diagnose and leave strategy) if no high-risk features are present.

Tipo de estudo

Intervencional

Inscrição (Estimado)

204

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Quebec
      • Montreal, Quebec, Canadá
        • Centre Hospitalier de l'Université de Montréal

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

45 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age 45-80 years
  • Undergoing an outpatient colonoscopy at the Centre Hospitalier de l'Université de Montréal (CHUM)
  • Signed informed consent form

Exclusion Criteria:

  • Inflammatory Bowel Disease;
  • Active colitis;
  • Hereditary CRC syndrome;
  • Coagulopathy;
  • American Society of Anesthesiologists (ASA) status >3

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: AI-assisted classification with endoscopist's input

AI-assisted classification for diminutive polyps during a colonoscopy procedure using the CAD-eye detection and classification system, with input from the endoscopist in the case of serrated polyps, for patients who agree to undergo optical diagnosis of diminutive colorectal polyps.

CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.

Outros nomes:
  • Olho CAD
Outro: Autonomous AI-assisted classification

AI-assisted classification for diminutive polyps during a colonoscopy procedure using the CAD-eye detection and classification system, with no input from the endoscopist, for patients who agree to undergo optical diagnosis of diminutive colorectal polyps.

CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.

Outros nomes:
  • Olho CAD

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Accuracy of the intracolonoscopy AI-assisted optical diagnosis
Prazo: 120 days

Using the optical diagnosis obtained from 2 experts as the reference, the accuracy of the intracolonoscopy AI-assisted optical diagnosis (OD, with endoscopist input or autonomous) is measured as the number of correct ODs out of all ODs (%).

120 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Proportion of patients who accept study participation
Prazo: 120 days

Number of patients who accept to participate out of all patients approached

120 days
Proportion of the patients unwilling to participate due to concerns regarding undergoing an optical diagnosis
Prazo: 120 days

The proportion of the patients unwilling to participate in the study due to the concerns of resect and discard or diagnose and leave strategies (with endoscopist input or autonomous) and preference upon histopathological evaluation of all detected polyps

120 days
Agreement between the intracolonoscopy AI-assisted optical diagnosis and the AI-assisted optical diagnosis by experts
Prazo: 120 days

The agreement between AI-assisted OD (with and without endoscopist's input) and the experts' OD is measured as the number of cases where both ODs are the same out of all cases (%).

120 days
Diagnostic characteristics of AI-assisted optical diagnosis using adjudication by two expert endoscopists as the reference standard
Prazo: 120 days

To calculate the accuracy, sensitivity, specificity, positive predictive value, negative predictive value of (CADx) assisted optical diagnosis (resect and discard) strategy using adjudication by two expert endoscopists as the reference standard.

120 days
Proportion of polyps with a low-confidence diagnosis
Prazo: 120 days

Proportion of polyps with a low-confidence diagnosis intracolonoscopy and later by the expert independent reviewers

120 days
Assessing cost savings through AI-assisted optical diagnosis
Prazo: 120 days

The reduction in costs of the supplies and the pathology assessments according to the expenses reported by the CHUM gastroenterology and pathology departments including the expenses related to the supplies (e.g., snares, containers), immediate and delayed complications, specimen processing and equipment and physician fees.

120 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Daniel von Renteln, MD, Centre hospitalier de l'Université de Montréal (CHUM)

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de setembro de 2023

Conclusão Primária (Real)

1 de maio de 2025

Conclusão do estudo (Estimado)

31 de agosto de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

22 de setembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de setembro de 2023

Primeira postagem (Real)

28 de setembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de setembro de 2026

Última verificação

1 de fevereiro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2024-11557/23.095

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever